Clinical economic evaluation : treatment of Budesonide/Formoterol compared to Budesonide on mild-moderate persistant asthma

Objectives It was a randomized,open-minded,parallel-group study,evaluating the clinical economic evaluation of budesonide/formoterol and budesonide alone in patients with mild-to-moderate persistant asthma.Methods 40 mild-to-moderate persistant asthma to outpatients were were randomized into 12 weeks of twice-daily inhaled treatment with either budesonide/formoterol,160μg/4.5μg(Symbicort Turbuhaler,AstraZeneca,Lund,Sweden),or budesonide,200 μg (Pulmicort Turbuhaler,AstraZeneca,Lund,Sweden)and inhaled salbutamol as needed.The cost-effectiveness analysis and increment cost-effectiveness of succeesful-treatment weeks,symptom free days and uninvolved days were evaluated after 12 weeks treatment.And the sensitivity analysis was also done.Results After 12 weeks treatment,the average of succeesful- treatment weeks, symptom free days and uninvolved days in budesonide/formoterol group were better than that of in budesonide group (P〈0.05).The average cost-effectiveness of succeesful- treatment weeks,symptom free days and uninvolved days in budesonide/formoterol group were better than that of in budesonide group (P〈0.05),which was not affected by cost.